Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from MBX Biosciences, Inc. ( (MBX) ).
On September 22, 2025, MBX Biosciences announced that its Phase 2 Avail trial for canvuparatide, a treatment for chronic hypoparathyroidism, achieved a 63% responder rate at 12 weeks and a 79% responder rate at six months in an open-label extension. The trial results, which showed significant improvements in bone and kidney biomarkers and a favorable safety profile, suggest that canvuparatide could simplify treatment regimens for patients and potentially become a best-in-class therapy, supporting the company’s plans to initiate a Phase 3 trial in 2026.
The most recent analyst rating on (MBX) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on MBX Biosciences, Inc. stock, see the MBX Stock Forecast page.
Spark’s Take on MBX Stock
According to Spark, TipRanks’ AI Analyst, MBX is a Underperform.
MBX Biosciences faces significant challenges with its zero revenue and increasing losses, heavily impacting financial performance. Bearish technical indicators and valuation concerns compound the risks. While the strategic board appointment is a positive step, it does not offset the primary financial and operational difficulties.
To see Spark’s full report on MBX stock, click here.
More about MBX Biosciences, Inc.
MBX Biosciences is a biopharmaceutical company based in Carmel, Indiana, focused on developing novel precision peptide therapies for endocrine and metabolic disorders. The company leverages its proprietary Precision Endocrine Peptide platform to advance a pipeline of candidates, including canvuparatide for chronic hypoparathyroidism, imapextide for post-bariatric hypoglycemia, and an obesity portfolio.
Average Trading Volume: 446,193
Technical Sentiment Signal: Strong Sell
Current Market Cap: $335.9M
For detailed information about MBX stock, go to TipRanks’ Stock Analysis page.